Cirrhosis News and Research

Latest Cirrhosis News and Research

Liver transplants worth risk for people who have genetic liver conditions, study finds

Patients faced with the diagnosis of a life-threatening liver disease have to consider the seriousness of having a liver transplant, which can be a definitive cure for many acquired and genetic liver diseases.

6 Apr 2013

Vertex to conduct two Phase 2 studies of VX-135 in combination with daclatasvir

Vertex Pharmaceuticals Incorporated today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertex's nucleotide analogue hepatitis C virus polymerase inhibitor VX-135 and Bristol-Myers Squibb's NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C.

6 Apr 2013

Blocked bile ducts can be effectively treated with metal stents

A multi-center analysis, led by Weill Cornell Medical College and published in the Journal of Clinical Gastroenterology, shows the use of temporary "fully covered self-expanding metal stents" (FCSEMS) can effectively fix a painful and potentially life-threatening benign biliary stricture -- a severely blocked or narrowed bile duct.

21 Mar 2013

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

Chronic hepatitis C infection is one of the most frequent chronic infectious diseases worldwide. The WHO estimates that 150 million people worldwide are chronically infected with the hepatitis C virus (HCV).

20 Mar 2013

EASL urges UK to press ahead with proposed implementation of minimum unit pricing of alcohol

According to WHO, liver cirrhosis accounts for 1.8% (i.e. 170,000) of all deaths in Europe. In recent years liver cirrhosis has become a serious health threat in some Western European countries such as Ireland and the United Kingdom, where over the last 10 years the associated mortality has increased.

15 Mar 2013

UK’s health performance declining compared with 14 EU countries over past 20 years

Six decades of universal free health care, the introduction of widespread public health initiatives (eg, tobacco control, cancer screening, and immunisation), and substantial increases in health expenditure have failed to improve the UK’s health outcomes or longevity ranking against the average of 14 other original members of the European Union, Australia, Canada, Norway, and the USA (EU15+) over the past 20 years.

6 Mar 2013

HIV might promote aging and disease progression in people with HCV, study results suggest

Infectious disease experts at Johns Hopkins have found that among people infected with the hepatitis C virus, co-infection with HIV, speeds damage and scarring of liver tissue by almost a decade.

5 Mar 2013

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).

5 Mar 2013

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia.

4 Mar 2013

Wnt-induced Lgr5 expression marks stem cell production in the liver

For decades scientists around the world have attempted to regenerate primary liver cells known as hepatocytes because of their numerous biomedical applications, including hepatitis research, drug metabolism and toxicity studies, as well as transplantation for cirrhosis and other chronic liver conditions. But no lab in the world has been successful in identifying and growing liver stem cells in culture -- using any available technique - until now.

26 Feb 2013

Janssen submits simeprevir regulatory application in Japan to treat HCV

Medivir AB today announced that its partner Janssen now has submitted a regulatory application to the Japanese Ministry of Health & Welfare authorities seeking approval for simeprevir, administered with pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C patients who are treatment naïve, prior non responders or relapsed following treatment with Peg-IFN with or without RBV.

22 Feb 2013

EASL unveils new publication - The burden of liver disease in Europe

Major progress has been made in the past 30 years in the knowledge and management of liver disease, yet approximately 29 million Europeans still suffer from a chronic liver condition. The European Association for the Study of the Liver (EASL) today unveiled its new publication The burden of liver disease in Europe: a review of available epidemiological data.

22 Feb 2013

Daclatasvir has two primary modes of action against HCV

A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir, a direct-acting antiviral agent in development for the treatment of hepatitis C virus (HCV), targets one of its proteins and causes the fastest viral decline ever seen with anti-HCV drugs - within 12 hours of treatment.

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Study may help design better DAA drug cocktails to treat HCV

Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs.

20 Feb 2013

Early PBC prognosis advocated

Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest.

18 Feb 2013

Researchers discover miR-27b that regulates lipid levels in the blood

Researchers have identified a microRNA liver gene, miR-27b, which regulates lipid (cholesterol or fat) levels in the blood. This regulator gene controls multiple genes involved in dyslipidemia-abnormal blood cholesterol levels that can contribute to heart disease.

11 Feb 2013

Donor liver quality: an interview with Dr Eric Orman

Liver transplantation is a surgical procedure in which a liver (or part of a liver) is removed from a donor and placed into a recipient. Although some transplants use a portion of the liver of living donors, the vast majority of donors are deceased.

6 Feb 2013

DHA more effective than EPA in preventing liver inflammation and fibrosis

Research at Oregon State University has found that one particular omega-3 fatty acid has a powerful effect in preventing liver inflammation and fibrosis - common problems that are steadily rising along with the number of Americans who are overweight.

6 Feb 2013

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Synageva BioPharma Corp. (Synageva), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology

5 Feb 2013

Cirrhosis News and Research

Latest Cirrhosis News and Research

Liver transplants worth risk for people who have genetic liver conditions, study finds

Vertex to conduct two Phase 2 studies of VX-135 in combination with daclatasvir

Blocked bile ducts can be effectively treated with metal stents

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

EASL urges UK to press ahead with proposed implementation of minimum unit pricing of alcohol

UK’s health performance declining compared with 14 EU countries over past 20 years

HIV might promote aging and disease progression in people with HCV, study results suggest

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

Wnt-induced Lgr5 expression marks stem cell production in the liver

Janssen submits simeprevir regulatory application in Japan to treat HCV

EASL unveils new publication - The burden of liver disease in Europe

Daclatasvir has two primary modes of action against HCV

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Study may help design better DAA drug cocktails to treat HCV

Early PBC prognosis advocated

Researchers discover miR-27b that regulates lipid levels in the blood

Donor liver quality: an interview with Dr Eric Orman

DHA more effective than EPA in preventing liver inflammation and fibrosis

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cirrhosis News and Research

Latest Cirrhosis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in